LGND
Ligand Pharmaceuticals Incorporated
298.40$
+0.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 14.2% | 8.1% | 5.1% | 3.8% | 2.5% | 9.4% | 18.6% | 25.7% | 26.9% | 26.7% | 6.6% | 2.5% | |
| 85.8% | 91.9% | 94.9% | 96.2% | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% | |
| 18.8% | 18.6% | 19.5% | 19.1% | 11.1% | 46.5% | 24.8% | 13.3% | 18.4% | 18.7% | 12.8% | 30.3% | |
| 35.0% | 33.9% | 24.4% | 20.3% | 15.0% | 34.8% | 36.7% | 19.4% | 35.7% | 40.2% | 47.1% | 34.5% | |
| 53.8% | 52.5% | 53.7% | 48.0% | 32.4% | -580.4% | 58.5% | 31.3% | 71.5% | 64.2% | 106.9% | 79.9% | |
| 30.4% | 38.0% | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% | |
| 7.5% | 16.4% | 11.2% | 8.1% | 19.2% | 29.7% | 16.8% | 8.1% | 0.9% | 0.5% | 1.8% | 1.8% | |
| 17.5% | 49.1% | 7.3% | 40.6% | 68.9% | 662.3% | 0.8% | 29.9% | 18.4% | 48.5% | 1.5% | 59.3% | |
| 0.6% | -305.4% | 9.5% | 31.7% | 11.9% | 139.1% | -3.2% | -1.7% | 21.0% | 7.5% | 3.9% | 12.9% | |
| 18.6% | 357.8% | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% | |
| 36.2% | 41.7% | 50.6% | 57.5% | 94.8% | 728.4% | 34.6% | 59.1% | 41.4% | 76.8% | 24.4% | 71.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.